|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4399-4405.
Prepublished online as a Blood First Edition Paper on February 6, 2007; DOI 10.1182/blood-2006-09-045104.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells
Letizia Venturini1,
Karin Battmer1,
Mirco Castoldi2,
Beate Schultheis3,
Andreas Hochhaus3,
Martina U. Muckenthaler2,
Arnold Ganser1,
Matthias Eder1, and
Michaela Scherr1
1 Department of Hematology, Hemostasis, and Oncology, Hannover Medical School, Germany;
2 Department of Pediatric Oncology, Hematology, and Immunology, University of Heidelberg, Germany;
3 III Medical Clinic, University Hospital of Mannheim, University of Heidelberg, Mannheim, Germany
Aberrant micro RNA (miRNA) expression has been described in human malignancies including B-cell lymphomas. We here report BCR-ABL– and c-MYC–dependent regulation of miRNA expression in chronic myeloid leukemia (CML) using microarray analysis (miCHIP) and miRNA-specific quantitative real-time reverse transcriptase–polymerase chain reaction (miR-qRT-PCR). In 3 bcr-abl–positive cell lines, expression of miRNAs encoded within the polycistronic miR-17-92 cluster is specifically down-regulated (2- to 5-fold) by both imatinib treatment and anti–BCR-ABL RNA interference (RNAi). In addition, anti–c-MYC RNAi reduces miR-17-92 expression in K562 cells in which miRNAs can specifically repress reporter gene expression, as demonstrated by specific miRNA inhibition with antagomirs. Furthermore, lentivirus-mediated overexpression of polycistronic miRNAs in K562 cells confers increased proliferation, partial resistance against anti–c-MYC RNAi, and enhanced sensitivity to imatinib-induced cell death. Finally, we determined miR-17-92 expression in purified normal (n = 4), early chronic-phase (CP) (n = 24), and blast-crisis (BC) (n = 7) CML CD34+ cells and found up-regulation of polycistronic pri-miRNA transcripts in CML and mature miRNAs in CP but not in BC CML. These data are in accordance with a BCR-ABL–c-MYC–miR-17-92 pathway that mediates enhanced miRNA expression in CP but not BC CML CD34+ cells. Altered miRNA expression may contribute to the pathophysiology of the disease and may provide potential targets for therapeutic intervention.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Bruchova, M. Merkerova, and J. T. Prchal
Aberrant expression of microRNA in polycythemia vera
Haematologica,
July 1, 2008;
93(7):
1009 - 1016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Urbich, A. Kuehbacher, and S. Dimmeler
Role of microRNAs in vascular diseases, inflammation, and angiogenesis
Cardiovasc Res,
July 1, 2008;
(2008)
cvn156v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M.-S. Tay, W.-L. Tam, Y.-S. Ang, P. M. Gaughwin, H. Yang, W. Wang, R. Liu, J. George, H.-H. Ng, R. J. Perera, et al.
MicroRNA-134 Modulates the Differentiation of Mouse Embryonic Stem Cells, Where It Causes Post-Transcriptional Attenuation of Nanog and LRH1
Stem Cells,
January 1, 2008;
26(1):
17 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Scherr, L. Venturini, K. Battmer, M. Schaller-Schoenitz, D. Schaefer, I. Dallmann, A. Ganser, and M. Eder
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function
Nucleic Acids Res.,
December 3, 2007;
35(22):
e149 - e149.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
